Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Erlotinib

Catalog No: tcsc0620

Available Sizes

Size: 1g

Size: 2g

Size: 5g

Size: 10g

Specifications

CAS No:
183321-74-6

Formula:
$C_{22}H_{23}N_3O_4$

Pathway:
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy

Target:
EGFR;EGFR;Autophagy

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 50 mg/mL (127.08 mM)

Alternative Names:
NSC 718781;OSI-744;R1415

Observed Molecular Weight:
393.44

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Erlotinib inhibits purified **EGFR** kinase with an **IC_{50}** of 2 nM.

IC50 & Target: IC50: 2 nM (EGFR)[1]

In Vitro: Erlotinib (CP-358,774) is also a potent inhibitor of the recombinant intracellular (kinase) domain of the EGFR, with an IC_{50} of 1 nM. The proliferation of DiFi cells is strongly inhibited by Erlotinib with an IC_{50} of 100 nM for an 8-day proliferation assay[1]. The combination of B-DIM and Erlotinib (2 μM) results in a significant inhibition of colony formation in BxPC-3 cells when compared with either agent alone. The combination of B-DIM and Erlotinib (2 μM) results in a significant induction of apoptosis only in BxPC-3 cells when compare with the apoptotic effect of either agent alone[2].

In Vivo: Under the experimental conditions, the combination of B-DIM and Erlotinib (50 mg/kg, i.p.) treatment shows significant decrease (P [2]. Erlotinib (20 mg/kg, p.o.) significantly attenuates Cisplatin (CP)-induced body weight (BW) loss when compared to the CP+vehicle (V) rats (P[3]